Provided by Tiger Trade Technology Pte. Ltd.

Tempest Therapeutics Inc.

0.8112
+0.00510.63%
Post-market: 0.8000-0.0112-1.38%19:59 EDT
Volume:2.27M
Turnover:1.86M
Market Cap:13.70M
PE:-0.18
High:0.8500
Open:0.8239
Low:0.7800
Close:0.8061
52wk High:12.23
52wk Low:0.7432
Shares:16.89M
Float Shares:9.60M
Volume Ratio:10.14
T/O Rate:23.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5617
EPS(LYR):-19.4955
ROE:-931.14%
ROA:-79.37%
PB:-12.57
PE(LYR):-0.04

Loading ...

Tempest Therapeutics - Files to Offer up to 8,910,579 Shares - SEC Filing

THOMSON REUTERS
·
Aug 22

Tempest Therapeutics Special Meeting Adjourned After Proposal Fell Short of Required Votes

Reuters
·
Aug 19

Tempest Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Tempest Therapeutics Enters USD 50 Million Equity Purchase Deal with Lincoln Park Capital Fund

Reuters
·
Aug 14

Tempest Therapeutics - Enters $50 Mln Common Stock Purchase Agreement with Lincoln Park - SEC Filing

THOMSON REUTERS
·
Aug 14

Press Release: Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14

Tempest Therapeutics Inc Expected to Post a Loss of 30 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Tempest Therapeutics Partners with Senlang Biotech to Advance Tpst-4003 in Vivo CAR-T into First-in-human Trial

Reuters
·
Jul 21

Tempest Announces Development Collaboration with Senlang Biotechnology for Tpst-4003, a Cd7-targeted Next-generation in Vivo CAR-T

THOMSON REUTERS
·
Jul 21

Tempest Therapeutics - Co and Senlang to Develop Tpst-4003 with Trial in China for Mg and MS

THOMSON REUTERS
·
Jul 21

Tempest Therapeutics - First Patient Dosing for Tpst-4003 Trial Expected in Q4 2026

THOMSON REUTERS
·
Jul 21

How Jakarta Plans to End Open Dumping in Bantargebang

Tempo
·
Jul 18

Tempest Therapeutics Plans First Clinical Study of in Vivo CAR-T Candidate Tpst-4003 in Q4 2026

Reuters
·
Jul 15

Rani Therapeutics Names Nicholas Maestas CFO, Replacing Svai Sanford

Reuters
·
Jun 29

Tempest Therapeutics Registers 2.43 Million Shares for Resale

MT Newswires Live
·
Jun 27

Tempest Therapeutics - Selling Stockholders May Offer up to 2.43 Mln Shares of Tempest Therapeutics Common Stock - SEC Filing

THOMSON REUTERS
·
Jun 27

Jakarta Offers Prizes for Waste Sorting on Anniversary Peak Night

Tempo
·
Jun 25

Tempest Therapeutics CEO Matthew Angel reports indirect purchase of 231,482 shares for $499,999.12

Reuters
·
Jun 24

Tempest Therapeutics shareholders approved Nasdaq Rule 5635 share issuances at special meeting

Reuters
·
Jun 23

Tempest Therapeutics director John D. Yee files initial beneficial ownership statement

Reuters
·
Jun 18